Astellas And Effector Cell Institute To Jointly Develop Autoimmune Drug
This article was originally published in PharmAsia News
Astellas Pharma has signed a licensing deal with Tokyo-based Effector Cell Institute to develop a new drug based on the novel target protein FROUNT in the area of autoimmune disorders, such as transplant rejection and rheumatoid arthritis. Under the license, Effector will receive an up-front payment and research fees, as well as development milestones related to the compound. (Click for more-Japanese language
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.